Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt by Beckerle, Mary C. & Kato, Takahiro
R e s e a r c h  a r t i c l e
A t r i a l  n a t r i u r e t i c  p e p t i d e  p r o m o t e s  
c a r d i o m y o c y t e  s u r v i v a l  b y  c G M P - d e p e n d e n t  
n u c l e a r  a c c u m u l a t i o n  o f  z y x i n  a n d  A k t
T a k a h iro  K a to ,1 J o h n  M u ra s k i,1 Y an  C h e n ,1 Y a su yu k i T s u jita ,1 J a s o n  W a ll,1 
C h r is to p h e r  C . G le m b o ts k i,1 E rik  S c h a e fe r,2 M a ry  B e c k e r le ,3 a n d  M a rk  A . S u s s m a n 1
1San Diego State University Heart institute, Department of Biology, San Diego, California, USA. 2Biosource International, Hopkinton, Massachusetts, USA. 
3Huntsman Cancer Institute, Departments of Biology and Oncological Sciences, University of Utah, Salt Lake City, Utah, USA.
T h is  s tu d y  d e lin e a te s  a  m e c h a n is m  f o r  a n t ia p o p t o t ic  s ig n a lin g  in i t ia t e d  b y  a t r ia l  n a t r iu r e t ic  p e p tid e  (A N P ) 
s t im u la t io n  le a d in g  to  e le v a tio n  o f  c G M P  le v e ls  a n d  s u b s e q u e n t  n u c le a r  a c c u m u la t io n  o f  A k t k in a s e  a s s o c ia te d  
w ith  z y x in , a  c y to s k e le ta l  L IM -d o m a in  p r o te in . N u c le a r  ta rg e t in g  o f  z y x in  in d u c e s  r e s is ta n c e  to  c e ll  d e a th  c o in ­
c id e n t  w ith  n u c le a r  a c c u m u la t io n  o f  a c tiv a te d  A k t. N u c le a r  t r a n s lo c a t io n  o f  z y x in  tr ig g e re d  b y  c G M P  a ls o  p r o ­
m o te s  n u c le a r  A k t  a c c u m u la t io n . A d d it io n a l s u p p o rtiv e  e v id e n c e  f o r  n u c le a r  a c c u m u la t io n  o f  z y x in -e n h a n c in g  
c a rd io m y o c y te  su rv iv a l in c lu d e s  t h e  fo llo w in g : (a )  p r o m o t io n  o f  z y x in  n u c le a r  lo c a l iz a t io n  b y  c a rd io p ro te c t iv e  
s t im u li ;  ( b )  z y x in  a s s o c ia t io n  w ith  p h o s p h o -A k t473 in d u c e d  b y  c a r d io p r o te c t iv e  s t im u l i ;  a n d  (c )  r e c r u i tm e n t  
o f  z y x in  to  th e  n u c le u s  b y  a c t iv a te d  n u c le a r - ta r g e te d  A k t  a s  w e ll a s  r e c r u i tm e n t  o f  A k t  b y  n u c le a r - ta r g e te d  
zy x in . N u c le a r  a c c u m u la t io n  o f  z y x in  re q u ire s  b o t h  A k t a c t iv a t io n  a n d  n u c le a r  lo c a l iz a t io n . P o te n t ia t io n  o f  c e ll  
s u rv iv a l i s  s e n s it iv e  to  s t im u la t io n  in te n s ity  w ith  h ig h -le v e l  in d u c t io n  b y  A N P  o r  c G M P  s ig n a lin g  le a d in g  to  
a p o p to t ic  c e l l  d e a th  r a th e r  th a n  e n h a n c in g  r e s is ta n c e  to  a p o p to t ic  s t im u li .  M y o c a rd ia l  n u c le a r  a c c u m u la t io n  
o f  z y x in  a n d  A k t  re s p o n d s  s im ila r ly  i n  v iv o  fo llo w in g  t r e a tm e n t  o f  m ic e  w ith  A N P  o r  cG M P . T h u s ,  z y x in  a n d  
a c tiv a te d  A k t  p a r t ic ip a te  i n  a  c G M P -d e p e n d e n t  s ig n a lin g  c a sc a d e  le a d in g  f r o m  A N P  re c e p to rs  to  n u c le a r  a c c u ­
m u la t io n  o f  b o t h  m o le c u le s .  N u c le a r  a c c u m u la t io n  o f  z y x in  a n d  a c tiv a te d  A k t  m a y  r e p r e s e n t  a  fu n d a m e n ta l  
m e c h a n is m  t h a t  fa c il i ta te s  n u c le a r -s ig n a l  t r a n s d u c t io n  a n d  p o te n t ia te s  c e l l  su rv iv a l.
In tro d u c tio n
M em bers o f  the natriu retic peptide family, atrial natriu retic 
peptide (ANP), brain natriuretic peptide, and C type natriuretic 
peptide, serve as physiological regulators o f  homeostasis including 
control o f  fluid retention and blood pressure. Clinical treatm ent 
o f  various cardiovascular pathologies shows that natriuretic pep­
tides exert beneficial effects in arterial hypertension (1, 2), myo­
cardial infarction (3), coronary artery disease (4 -7 ), and chronic 
heart failure (8 -13). Collectively, these results suggest that ANP 
is cardioprotective at a plasma concentration o f  approximately 3 
ng/ml (10 9 M) in treated patients, in agreement with in vitro data 
using 10 9 M  ANP exposure to inhibit apoptotic cell death induced 
by serum deprivation in cultured nonm yocytes (14) as well as 
sim ilar protective effects in other cells (15, 16). In com parison, 
relatively high ANP concentrations (10 7 M) prom ote apoptosis 
in various cell types (17-18). These data suggest that very different 
effects o f  ANP on preventing or inducing apoptosis may occur at 
therapeutic (10 9 M) or experimentally elevated (10 6 M) concen­
trations, respectively. Antiapoptotic effects o f  natriuretic peptide 
are mediated via activation o f  particulate guanylyl cyclases (pGCs) 
that modify GTP to elevate intracellular cGM P levels. Increases 
in cardiac cGM P levels inhibit ischemia/reperfusion damage by 
activation o f  the Akt/Bad/Bcl2 signaling pathway that prevents
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apoptotic cell death (19). Protective effects o f  cGM P may involve 
downstream activation o f  cGMP-dependent PKG, expressed in car- 
diomyocytes as the PKG 1 (but not PKG 11) isoform (20), since PKG 
activates P13K/Akt kinase signaling in vascular sm ooth muscle 
and endothelial cells (21-25). The ANP/cGMP/PKG signaling cas­
cade is well known for antiapoptotic activity in neuronal cell types
(26) but is relatively unstudied in cardiomyocytes. However, ANP- 
induced cGM P signaling could certainly prom ote antiapoptotic 
responses in cardiomyocytes via Akt activation, since the protec­
tive effects o f  Akt in the myocardium are well known (27-29).
The mechanism(s) o f  Akt-mediated activation and antiapoptot­
ic signaling in cardiomyocytes remain(s) enigm atic despite con ­
tinued progress from m ultiple laboratories. Akt accum ulates in 
the nucleus following stim ulation with cardioprotective stim uli 
such as 1GF-1 (30) or estrogen (31), suggesting that biologically 
relevant targets are located in the nuclear com partm ent. Our pre­
vious studies indicate that nuclear targeting o f  Akt exerts potent 
antiapoptotic action in the myocardium and isolated cardiomyo­
cytes (32). Recently, a cytoskeletal focal adhesion com ponent 
named zyxin was dem onstrated to accum ulate in the nucleus o f  
vascular sm ooth muscle cells following m echanical stretch and 
redistribute in response to ANP or an active cGM P analog (33, 
34). Intriguing properties o f  zyxin, such as an inherent nuclear 
exclusion sequence (NHS), possession o f  m ultiple LIM -dom ain 
motifs sharing homology with transcription factors, and constitu­
tive shuttling through the nucleus in cultured fibroblasts (35) all 
implicate this protein in nuclear-signal transduction. Collectively, 
these observations suggest that redistribution o f  zyxin from  the 
cytoskeleton to the nucleus serves as a signaling m echanism  for 
transm ission o f  ANP-mediated effects.
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ANP exposure exerts concentration-dependent antiapoptotic effects upon cardiomyocytes and is protective in vivo. (A) Cardiomyocytes 
were plated onto chamber slides and preincubated with or without ANP (concentration range from 10~10 5 M to 10~6 M as indicated for 1 hour) 
followed by 2 hours of vehicle only (-) or staurosporine treatment (+; 1 nM). Apoptosis was assessed by TUNEL assay. (B) Apoptotic sig­
naling in cultured cardiomyocytes evaluated by cleaved caspase-3. Quantitation of caspase-3 immunoblot was performed by densitometric 
analysis using GAPDH as a loading standard to correct for slight differences in protein loading. ANP treatment protocol was the same 
as in A. (C) Cardiomyocytes were treated with ANP for 24 hours prior to 2 hours apoptotic stimulus with staurosporine. Apoptosis was 
assessed by TUNEL assay. (D) Circulating serum levels of ANP from mice implanted with osmotic pumps as determined by ELISA assay 
(see Methods; n = 4 for each group). (E-H) Analyses of hearts from mice implanted with osmotic pumps (saline control versus ANP treated) 
or genetically engineered to express nuclear-targeted zyxin (nontransgenic [NTg] control versus nuclear-targeted zyxin [zyxin-n.t.]) as 
described in Methods. (E) Representative confocal micrographs of TUNEL assays performed on myocardial sections of hearts subjected to 
ischemia/reperfusion damage. Scale bars: 10 nm. (F) Quantitation of TUNEL-positive nuclei from myocardial sections of mice as indicated. 
(G-H) Recovery of hemodynamic function during reperfusion phase for mouse groups receiving osmotic pump implants (G) or genetically 
engineered to express nuclear targeted zyxin (H). *P  < 0.05 or **P < 0.01 for each indicated comparison in A-H. n = 3 for experiments in 
A-C; n = 4 for experiments in D-H. LVDP, left ventricular developed pressure.
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ANP induces nuclear accumulation of zyxin at antiapoptotic concentration. Immunolabeling (A and B) and quantitation of nuclear labeling 
(C and D) in cultured cardiomyocytes treated with ANP (1(H for 1 hour for A, B, and D; 1(H M for 1 hour also shown for B). Immunolabeling 
at high (A) and low (B) magnification shows zyxin (green in overlay) predominantly associated with myofibrillar striations and focal adhesion 
regions in periphery of untreated cells (control). 1(H  M ANP treatment resulted in redistribution and nuclear accumulation of zyxin whereas 
nuclear accumulation did not occur at 1 (H  M ANP. Myofibrillar organization was observed with phalloidin to label actin filaments (red in overlay). 
Bar measurements in micrographs represent distance in nm. Quantitation (C) shows dosage-dependent nuclear accumulation of zyxin peak at 
10-9 M ANP 2 hours after treatment. Time course of nuclear zyxin accumulation (D) shows peak level within hours after treatment and return to 
normal level within 24 hours, n = 3 for all experiments. *P < 0.01.
Results presented here reconcile ANP-related observations regarding 
cell survival with activation o f  cGMP-dependent signaling cascades 
leading to nuclear accumulation o f  Akt in cardiomyocytes. Further­
more, connections are established between ANP-mediated Akt activ­
ity and redistribution o f  zyxin from the cytoskeleton to the nucleus. 
Delineating the signaling mechanisms for ANP-mediated antiapop­
totic activity mediated through cGMP-dependent Akt activation in 
cardiomyocytes is an important factor in understanding therapeutic 
applications o f natriuretic peptides in the treatment o f heart failure.
R e su lts
Antiapoptotic effect ofANP exposure upon cardiomyocytes varies with con­
centration. Cultured cardiomyocytes were pretreated with vehicle or 
ANP at concentrations o f  10 m \ 10 9, 10 7~\ or 10 6 M followed by
2-hour exposure to apoptotic stim ulation with 1 staurosporine 
treatment. DNA cleavage in cells undergoing apoptosis was detect­
ed by TUNEL assay in conjunction with confocal microscopy. ANP 
treatm ent produced significantly different effects based upon 
concentration. ANP concentrations between 10 ,0'5 and 10 75 M 
were antiapoptotic, protecting cardiomyocytes from staurosporine 
challenge and decreasing TUNEL-positive nuclei compared with 
controls (Figure 1A), although the protective effect was maximal at 
a low therapeutic dose o f  10 9 M. In contrast, a higher dose o f  ANP 
(10 6 M) increased TUNEL-positive nuclei by 2-fold (202% ± 11.2%) 
in cardiomyocytes w ithout any additional apoptotic stimuli. The 
proapoptotic effect o f  ANP at high concentrations was confirmed 
by dem onstration o f  a 7- fold increase in cleaved caspase-3 rela­
tive to that in vehicle-treated control cell cultures (Figure IB ).
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Nuclear accumulation of zyxin is antiapoptotic. TUNEL assay (A) of cultured cardiomyocytes infected with adenoviruses expressing GFP, full- 
length zyxin (zyxin-w.t.), or nuclear-targeted zyxin for 2 hours followed by treatment with 1 umol/l staurosporine to induce apoptosis. Results 
shown were derived from 3 separate experiments. (B) Apoptosis in cultured cardiomyocyte evaluated by DNA laddering. Adenoviruses express­
ing p-gal or zyxin as wild-type, GFP-conjugated full length (GFP), residues 1 -322 (N-term), residues 349-542 (C-term), or NES-deleted residues 
322-331 (NES). Apoptotic stimulation was initiated by overexpression of pyk2 kinase as previously described (35). Typical result is shown of 3 
separate repetitions for the laddering experiment. (C) TUNEL assay of cultured cardiomyocytes shows protective effect of nuclear-targeted zyxin 
accumulation in response to apoptotic challenge by ANP (10-® M) but lack of protection by ANP (10~9 M) in response to apoptotic challenge by 
full-length wild-type zyxin accumulation. Adenoviral vectors were used for expression of zyxin constructs with GFP expression shown as a control 
for effects of ANP treatments. *P < 0.01; **P < 0.05.
Although 10 6 M ANP alone increased accum ulation o f  cleaved 
caspase-3 w ithout staurosporine, the same concentration found 
effective at lowering TUNHL labeling (10 9 M) also protected  
against staurosporine challenge and decreased caspase-3 cleav­
age (Figure IB ). Protective effects o f  10 9 M ANP against stauro- 
sporine-induced cell death persisted for up to 24 hours following 
treatm ent (Figure 1C), indicating that triggering o f  survival sig­
naling by ANP promotes prolonged antiapoptotic effects. Collec­
tively, these results indicate that ANP inhibits or promotes cardio­
myocyte apoptosis depending upon concentration. ANP-mediated 
protective effects were confirm ed in the intact myocardium using 
an ex vivo isolated heart model o f  ischemia/reperfusion damage. 
Mice implanted with an osm otic pump exhibited ANP serum con ­
centrations o f  1.6 x 10 m at tim e o f  sacrifice (Figure ID ), when 
hearts were harvested and challenged with ischemia/reperfusion 
injury. ANP treatm ent reduced apoptotic cell death quantitated 
with TUNHL assays by 68.8% compared with that in control hearts 
from mice receiving osm otic pumps with vehicle alone (Figure 1, 
H and F). Furthermore, hemodynamic assessments on hearts from 
mice treated with ANP showed improved functional recovery fol­
lowing reperfusion (Figure IG ; 2.1-fold higher left ventricular- 
developed pressure at 60 minutes).
ANP induces nuclear accumulation o f  zyxin at antiapoptotic concentra­
tions. Cultured cardiomyocytes were exposed to ANP at concentra­
tions found to either prom ote or inhibit apoptosis (10 6 M ver­
sus 10 9 M, respectively; Figure 1) to determine the effect upon 
intracellular distribution o f  zyxin. Zyxin is localized along myo­
fibrils and concentrated at focal adhesions in unstim ulated car­
diomyocytes (Figure 2, A and B, top panels), consistent with the 
role o f  this protein as a cytoskeletal-membrane constituent. Zyxin
undergoes a marked intracellular redistribution in response to 
treatm ent o f  cells with 10 9 M ANP, characterized by translocation 
and accumulation in the nucleus (Figure 2, A and B). Nuclear accu­
m ulation o f  zyxin occurs in a majority o f  the cells at ANP concen­
trations o f  10 9 M but not at the higher dose o f  10 6 M (Figure 2B) 
in a concentration-dependent fashion (Figure 2C). The induction 
o f  zyxin nuclear accum ulation by ANP peaks within 5 hours after 
exposure and returns to basal levels w ithin 24 hours after treat­
m ent (Figure 2D). These results indicate that ANP can prom ote 
nuclear accumulation o f  zyxin at the same concentration found to 
exert antiapoptotic signaling in cultured cardiomyocytes. Further­
more, a higher concentration o f  ANP found to be proapoptotic 
(10 6 M) does not prom ote nuclear accum ulation o f  zyxin.
Nuclear accumulation o f  zyxin is antiapoptotic. The association between 
antiapoptotic action o f  ANP and nuclear accum ulation o f  zyxin 
suggests a potential mechanism for protective cell signaling via 
nuclear zyxin accumulation. This postulate was tested by construct­
ing adenoviruses expressing zyxin either as full-length wild-type or 
full-length nuclear-targeted protein versions. The efficacy o f  these 
zyxin constructs in inhibiting cardiomyocyte apoptosis in response 
to staurosporine challenge was examined by both TUNHL assay and 
DNA laddering (Figure 3, A and B, respectively). Nuclear targeting 
o f  zyxin in TUNHL assays was accomplished by fusion o f  the zyxin 
cDNA to a multimerized series o f  nuclear localization sequences at 
the C terminus o f  the molecule. Comparison o f  the TUNHL results 
showed that full-length zyxin prom oted DNA cleavage but that 
nuclear targeting o f  zyxin abrogated the increase in TUNHL label­
ing (Figure 3A). Furthermore, TUNHL assay results showed that the 
nuclear-targeted zyxin construct significantly inhibited staurospo- 
rine-induced DNA cleavage. This protective effect was unique to the
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Nuclear accumulation of activated Akt kinase in response to ANP treatment or expression of nuclear-targeted zyxin. Cultured cardiomyocytes 
(A-Z) or myocardial sections (AA-JJ) showing nuclear accumulation of Akt. Confocal micrographs (A) and immunoblot analysis (B) of myo­
cytes treated with vehicle (control) or ANP (1 (H  M) show nuclear accumulation of both zyxin and phospho-Akt473 (p-Akt) in response to ANP 
exposure. Overlay channels in A correspond to zyxin (red), phospho-Akt (green), and actin filaments to show myofibril organization (blue). In
B, immunoblots for GAPDH, histone H3, and connexin 43 demonstrate subcellular fractionation of the cytosolic, nuclear, and membrane frac­
tions, respectively. Also shown are confocal micrographs of cardiomyocytes labeled with antibodies (shown in red) to either total Akt (C-N) or 
phospho-Akt473 (O-Z). Cells were infected with adenovirus (shown in green) expressing GFP (K-N and W-Z), nuclear-targeted zyxin (C-F and
O-R), or full-length zyxin (G -J and S-V). Myofibrillar organization was observed with phalloidin to label actin filaments (shown in blue). (C-N) 
Akt immunoreactivity was mainly observed in cytoplasm in cultures expressing full-length zyxin or GFP but accumulated in the nucleus following 
expression of nuclear-targeted zyxin virus. (O-Z) Phospho-Akt473 immunoreactivity was observed at low levels in cells expressing either full- 
length zyxin or GFP but accumulated in the nucleus following expression of nuclear-targeted zyxin. Myocardial sections (AA-JJ) show nuclear 
accumulation of phospho-Akt473 in transgenic mice expressing cardiac-specific nuclear-targeted zyxin (zyxin-n.t. Tg) but not in nontransgenic 
control samples. Arrows indicate nuclei positive for both zyxin and phospho-Akt473. Transgenic zyxin was visualized using antibody to myc-tag 
(tag) and desmin to show myofibrillar structure. Overlay colors correspond to phospho-Akt473 (red), myc-tag (green), nuclei (pink), and desmin 
(blue) with coincidence of red and blue labeling appearing yellow. Scale bars: 20 um (A and AA-JJ); 30 um (C-Z).
nuclear-targeted zyxin construct as uninfected, GFP-expressing, and 
full-length zyxin-expressing cardiomyocytes all showed comparable 
TUNHL labeling following staurosporine challenge. The com bina­
tion o f  staurosporine and full-length zyxin together showed the 
highest level o f  TUNHL labeling o f all conditions examined, clearly 
dem onstrating that cytoplasmic accum ulation o f  zyxin was not 
protective in response to staurosporine challenge (Figure 3A). DNA 
laddering assays (Figure 3B) confirmed and extended the results 
obtained by TUNHL assays by using additional adenoviral constructs 
o f  zyxin. Adenoviruses tested in the DNA laddering assay included 
full-length wild-type zyxin, GFP-tagged zyxin, the region o f zyxin 
prior to the endogenous NHS (amino-terminal residues 1-321), the 
LIM-domain region o f  zyxin following endogenous NHS (carboxyl- 
terminal residues 34 9 -5 4 2 ), and a construct lacking endogenous 
NHS-deleted residues 322-331) previously reported to accumulate 
in the nucleus (36). Apoptotic stimulation in DNA laddering experi­
ments was provided by overexpression o f pyk2 kinase that had been 
previously shown to be apoptotic in cultured cardiomyocytes (37). 
Consistent with previously observed TUNHL assay results, the cyto­
plasmic accumulation o f zyxin, either in full-length or truncated 
form, promoted DNA cleavage either alone or in combination with 
pyk2 (Figure 3B). In contrast, the NHS-deleted zyxin construct that 
accumulated in the nucleus was the only overexpressed protein to 
inhibit pyk2-induced apoptosis. Assessing the balance between ANP 
exposure and zyxin accumulation, nuclear-targeted zyxin expression 
inhibited the proapoptotic effect o f 10 6 M  ANP exposure, but stimu­
lation o f cells with 10 9 M  ANP failed to inhibit apoptotic cell death 
induced by overexpression o f wild-type zyxin (Figure 3C). Apoptotic 
signaling induced by the accumulation o f  overexpressed wild-type 
zyxin was apparently too strong to be overcome by ANP administra­
tion operating at near-physiologic concentration. The antiapoptotic 
effect o f  nuclear-targeted zyxin was confirmed in vivo using hearts
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Nuclear accumulation of zyxin is mediated by cGMP-dependent signaling. Time course of zyxin nuclear accumulation in cultured cardiomyocytes 
treated with cGMP (10"4 M). (A) Confocal microscopy shows distribution of zyxin (green in overlay) and myofibrils (red in overlay) following exposure 
to cGMP. Cells were labeled with phalloidin (actin filament) to reveal sarcomeric organization. Scale bars: 30 um. (B) Time course of nuclear zyxin 
accumulation shows peak level within minutes after treatment and return to normal level within 3 hours. (C) Activation of PKA or PKC signaling did 
not induce zyxin nuclear translocation. Bar graph shows the ratio of zyxin nuclear translocation with cGMP (10-4 M), PMA (10 ng/ml), orforskolin 
(10"5 M) treatment for 1 hour as assessed by confocal microscopy. (D) Participation of ANP or PKG in nuclear translocation of zyxin was demon­
strated by use of HS142-1 (ANP receptor inhibitor; 10 ug/ml) or KT5823 (PKG inhibitor; 5 x 10~6 M). Bar graph shows the ratio of zyxin nuclear 
translocation with or without inhibitor pretreatment followed by stimulation with cGMP (10-4 M) or ANP (10~9 M). n = 3 for all experiments.
from transgenic mice. Myocardial-specific transgenic expression o f 
nuclear-targeted zyxin significantly inhibited TUNHL labeling o f 
nuclei in sections o f  hearts challenged by ischemia/reperfusion dam­
age (Figure 1, H and F) and improved recovery o f  contractile function 
during the reperfusion phase (Figure 1H). Collectively, these findings 
are consistent with nuclear accumulation o f  zyxin mediating anti- 
apoptotic effects in cardiomyocytes, consistent with the postulate 
that zyxin is involved in protective effects mediated by ANP.
Nuclear accumulation o f  zyxin induces nuclear accumulation o f  activated 
Akt kinase. Antiapoptotic effects mediated by nuclear accumulation 
o f  zyxin (Figure 2) are reminiscent o f  the survival kinase Akt that 
accumulates in the nucleus and inhibits apoptosis (33). This cir­
cumstantial correlation was pursued in experiments to determine i f  
nuclear accumulation o f  zyxin prompted coincident nuclear accu­
mulation o f activated Akt. Cultured cardiomyocytes stimulated with
10 9 M ANP showed coincident nuclear accumulation o f  both zyxin 
and phospho-Akt473 by immunofluorescence microscopy (Figure 4A) 
and increased partitioning o f  both zyxin and phospho-Akt473 to the 
nuclear fraction by immunoblot analyses (Figure 4B). Appropriate 
partitioning o f  cellular components was checked by immunolabel- 
ing with antibodies to connexin 43 (cell membrane) and histone 
(nucleus). Confocal microscopy o f  cardiomyocytes infected with 
adenoviruses expressing GFP alone, GFP-tagged full-length zyxin, 
or GFP-tagged nuclear-targeted zyxin showed that nuclear accu­
mulation o f  GFP-tagged nuclear-targeted zyxin promoted concur­
rent nuclear accum ulation o f  Akt (Figure 4, C-N ). Furtherm ore, 
similar analyses using an antibody against phospho-Akt473 showed 
that nuclear-localized Akt was phosphorylated, indicative o f  kinase 
activation (Figure 4 ,0 -Z ). In contrast, overexpression o f  either GFP 
alone or GFP-tagged full-length zyxin did not prom ote nuclear
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Elevation of cGMP induces rapid nuclear accumulation of activated Akt 
kinase. cGMP and ANP increased the expression level of phospho-Akt in 
the nuclear fraction. Cells were labeled with phalloidin (A, leftside) to reveal 
sarcomeric organization. Confocal microscopy shows the nuclear accumu­
lation of phospho-Akt increase in the cardiomyocyte with cGMP (1CH M) 
or ANP (1 CH> M) treatment (A, middle). Actin filament (red) and zyxin 
(green) are depicted in overlay panels (A, right side). Scale bars, 60 nm. 
(B and C) Bar graph shows the ratio of the nuclear accumulation of phos­
pho-Akt with cGMP (1CH M) or ANP (1CH3 M) treatment obtained from 
confocal microscopic analysis, n = 3. *P < 0.05.
accumulation o f Akt. Prom otion o f  nuclear Akt accumulation by 
nuclear-targeted zyxin was confirm ed in vivo using hearts from 
transgenic mice. Myocardial-specific transgenic expression o f nucle­
ar-targeted zyxin increased nuclear labeling for phospho-Akt473 as 
demonstrated by confocal microscopy (Figure 4, AA-JJ). Together, 
these results indicate that nuclear accum ulation o f  activated Akt 
kinase is likely to play an important role in the antiapoptotic effects 
resulting from nuclear accumulation o f zyxin.
Nuclear accumulation o f  zyxin is mediated by cGMP-dependent signaling. 
Circum stantial associations exist between ANP-mediated effects 
and activation o f  cGMP-dependent signaling (26). To establish a 
cGMP-dependent mechanism for ANP-mediated effects upon zyxin, 
cultured cardiomyocytes were treated with 10 4 M  8-bromo-cGMP (a 
cell-permeable cGMP analogue) and analyzed by confocal microsco­
py. Zyxin nuclear translocation occurred within minutes after initia­
tion o f cGMP signaling, peaked after 1 hour, and returned to levels 
comparable to basal stimulation within 2 hours (Figure 5, A and B). 
Nuclear accum ulation o f  zyxin was unaffected by activators o f
cAMP-dependent (forskolin) or PKC-dependent (PMA) signaling 
at the 1-hour peak time point (Figure SC and Supplemental Fig­
ure S I ; supplemental material available online with this article; 
doi:10.1172/JC124280D Sl), suggesting the effect is specific to 
cGMP. Involvement o f  ANP receptor-mediated signaling in pro­
motion o f  zyxin nuclear accumulation was confirmed using HS- 
142-1 (an ANP receptor inhibitor), which blocked nuclear accu­
mulation o f zyxin when cultures were treated with the inhibitor 
prior to ANP exposure (Figure 5D) but alone had no effect upon 
zyxin localization (Supplemental Figure S2). However, HS-142-1 
did not block zyxin accum ulation in the nucleus initiated by 
cell-permeant cGMP, indicating that cGMP lies downstream o f 
ANP-receptor activation. cGMP-dependent signaling in media­
tion o f zyxin nuclear accumulation was confirmed using KT5823 
(a specific PKG inhibitor), which alone had no effect upon zyxin 
localization (Supplemental Figure S2) but abrogated nuclear 
accum ulation o f  zyxin when cultures were treated with the 
inhibitor prior to cGM P or ANP exposure (Figure 5D). These 
results implicate a cGM P-dependent pathway through natri­
uretic peptide receptor signaling in the nuclear accumulation o f 
zyxin mediated by ANP treatment.
Elevation o f  cGMP or ANP treatment induces rapid nuclear accu­
mulation o f  activated Akt kinase. The connection between ANP, 
zyxin, and Akt (Figures 2 -4 ) in con junction with dependence 
o f  zyxin nuclear accum ulation upon cGM P-dependent signal­
ing (Figure 5) suggests that nuclear accum ulation o f  activated 
Akt also involves cGM P-m ediated signaling. The association 
o f  cGM P-m ediated signaling and nuclear accum ulation o f  
Akt was dem onstrated by confocal m icroscopy o f  cultured 
cardiomyocytes treated with cell-permeant cGM P analog for
1 hour (Figure 6A). Q uantitation showed more than a 2-fold 
increase in phospho-A kt473 nuclear accum ulation following 
cGM P treatm ent that was statistically significant (Figure 6B; 
2.3 ± 0.31, P  '  0.05). Similarly, treatm ent o f  the cultures with 
ANP for 1 hour also significantly increased nuclear-localized 
phospho-Akt473 more than 2-fold (Figure 6C; 2.5 ± 0 .24 fold, 
P  '  0.05). Collectively, these results establish induction o f nucle­
ar Akt accum ulation by cGM P-dependent signaling and sup­
port the connection between ANP-mediated protective effects 
and cGMP-dependent accum ulation o f Akt in the nucleus.
Antiapoptotic effect ofcGM P exposure varies with concentration. 
ANP exerted opposing effects upon cell survival depending 
upon concentration (Figure 1) that could be related to the intensi­
ty o f  cGMP-dependent signaling activity initiated by ANP. Effects 
o f  varying cGM P concentrations upon apoptotic cell death were 
assessed by TUNHL assay using cultured cardiomyocytes. Treat­
ment with cell-permeant cGM P produced significantly differing 
effects based upon concentration. cGM P at a low concentration 
o f 10 4 M  was antiapoptotic, protecting cardiomyocytes from the 
staurosporine challenge and decreasing TUNHL-positive nuclei by 
37.8% ± 4.4% compared with that o f  controls (Figure 7). In contrast, 
a higher dose o f  cGMP alone at 10 2 M  increased TUNHL-positive 
nuclei over 3-fold (320% ± 7.6%) and at this higher concentration 
was ineffective at lowering TUNHL-positive cells in response to 
staurosporine challenge. Collectively, these results indicate that, 
like ANP, cGM P acts to  inhibit or prom ote cardiomyocyte apop­
tosis depending upon concentration.
Cardioprotective stimuli induce nuclear accumulation o f  zyxin. In addi­
tion  to ANP, other paracrine factors touted as cardioprotective 
agents are known to increase cGM P levels (38-40). Since nuclear
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accum ulation o f  zyxin is ANP- and cGM P-dependent (Figure 5), 
the abilities o f  various cardioprotective agents to mediate nuclear 
accumulation o f  zyxin were examined by confocal microscopy. The 
time course for nuclear zyxin accum ulation resulting from treat­
ment o f  cultured cardiomyocytes with 1GF-1, adrenomedullin, 
and estradiol are shown in Figure 8. In  com parison to the effect 
o f  ANP (Figure 2D), IGF showed a similar strong and rapid induc­
tion o f  nuclear zyxin accumulation in over 65% o f  cells that decayed 
over a 24-hour period. A similar cycle o f  rapid induction and decay 
occurred with adrenomedullin, albeit with a somewhat weaker 
response o f  slightly above 40% positive nuclei. Estradiol treatment 
produced a unique biphasic change in nuclear accum ulation o f 
zyxin that differed from the other 3 factors tested. Recurrence o f 
nuclear zyxin accum ulation in the later phase o f  estradiol treat­
ment may stem from autocrine or paracrine action o f  AN P induced 
by estrogen stim ulation (39). Treatm ent with the PKG inhibitor 
KT 5823 blocked nuclear accumulation o f  zyxin induced by any o f 
these cardioprotective stim uli (Figure 8D). These results indicate 
that the nuclear accum ulation o f  zyxin is a general characteristic 
o f  multiple cardioprotective stim uli that is dependent upon PKG 
activity, although differences in the kinetics and intensity o f  nucle­
ar accumulation occur depending upon the inducing agent used.
ANP induces nuclear accumulation o f  zyxin in the myocardium. Obser­
vations o f  cGM P- and ANP-mediated nuclear accum ulation in 
cultured cardiomyocytes were reproduced in the myocardium o f 
norm al mice as assessed by confocal microscopy and im m unoblot 
analyses (Figure 9). ANP was adm inistered continuously for 24 
hours through implantation o f  a subcutaneous osmotic pump iden­
tical to the protocol followed for TUNEL assays (Figure 1, E and F) 
and myocardial sections examined by confocal microscopy. Zyxin 
is distributed in costameres o f  cardiomyocytes with a striated pat­
tern predominantly coincident with sarcomeric desmin and is not 
detectable in nuclei o f  vehicle-treated control hearts but could 
be observed in nuclei o f  mice receiving ANP treatm ent (Figure 9, 
A-H, arrows) although desmin labeling remained unaffected. Fur­
thermore, transgenic mice with cardiac-specific expression o f  con­
stitutively active GC (41) also showed increased nuclear accumula­
tion o f  zyxin (Figure 9 ,1-P), implicating cGMP-mediated signaling 
in the prom otion o f  zyxin nuclear accum ulation. Observation o f  
nuclear phospho-Akt473 im m unoreactivity showed induction o f 
nuclear localization comparable to that observed for zyxin. Myo­
cardial sections o f  nontransgenic control mice receiving the ANP 
osm otic pump treatm ent showed increased nuclear labeling for 
phospho-A kt473 (Figure 9, Q -B B , arrows). Com parable results
F ig u re  7
Antiapoptotic effect of cGMP exposure varies with concentration. 
TUNEL assay shows effect of cGMP treatment upon apoptosis induced 
by staurosporine (1 uM) in cultured cardiomyocytes at low (10-4) or 
high (10~2) concentration. *P < 0.01; **P < 0.05.
yielding increased nuclear phospho-Akt473 labeling were obtained 
by bolus injection o f  cGM P (Figure 9, Q -B B , arrows). In addition, 
nuclear labeling for phospho-Akt473 was increased in transgenic 
mice with cardiac-specific expression o f  constitutively active GC 
(Figure 9, CC-JJ, arrows). Myocardial protein lysates processed for 
nuclear fractionation showed that ANP osm otic pump treatment 
increased nuclear accum ulation o f  zyxin and phospho-A kt473 
(Figure 9KK). Thus, zyxin and phospho-Akt473 nuclear accumula­
tion in vivo responds to the same inductive stim uli that promote 
nuclear accum ulation o f  these proteins in cultured cardiom yo­
cytes in association with elevated cGM P signaling.
Cardioprotective stimuli induce association o f  activated Akt with 
zyxin. Coincidence o f  nuclear accum ulation between zyxin and 
Akt (Figure 4) together w ith sim ilar actions o f  ANP or cG M P 
to  p rom ote nuclear accu m u lation  (Figures 2 and 5) suggest 
the potential for association  between zyxin and activated Akt 
kinase. Form ation o f  a m ultim olecular com plex involving zyxin 
and Akt was assessed by im m unoprecipitation using antibodies 
against p hospho-A kt473 followed by subsequent im m u noblot 
d etection  for zyxin. No such com plex between zyxin and Akt 
could  be d etected  in co n tro l v eh icle-treated  cardiom yocytes
F ig u re  8
Cardioprotective stimuli induce nuclear accumulation of zyxin that 
depends upon PKG activity. Time course of zyxin nuclear accumulation 
following treatment of cultured cardiomyocytes with various antiapop­
totic agents as indicated below the x axis of each graph is shown. Line 
graphs show the percentage of cells possessing nuclear localized zyxin 
following treatment with IGF-1 (A; 10~7 M), adrenomedullin (B; 10~7 M), 
and estradiol (C; 10~7 M) as assessed by confocal microscopy. Nuclear 
accumulation induced by any of the stimuli in A -C was inhibited by 
pretreatment of the cultures with KT5823 (PKG inhibitor; 5 x 10-® M) as 
shown in D. n = 3 for all experiments. *P < 0.05; **P < 0.01.
The Journal of Clinical Investigation http://www.jci.org Volume 115 Number 10 October 2005 2723
r e s e a r c h  a r t i c l e
Zyxin Nuclei a-actinin Overlay p-Akt Nuclei Desmin Overlay
F ig u re  9
ANP induces nuclear accumulation of zyxin and phospho-Akt in the myocardium. Myocardial sections (A-JJ) and immunoblot (KK) demonstrating 
nuclear accumulation of zyxin or phospho-Akt473. All ANP treatments were performed for 24 hours using an implanted osmotic pump with 200 |il 
of lO ^M  ANP. For all cGMP treatments, agonist at a concentration of 10~2 M was administered intravenously in 100 jil volume, and hearts were 
removed 5 hours later. (A-P) Control (A-D and l-L ) or experimental mice (E-H and M-P) labeled with antibody to zyxin (A, E, I, and M; green in 
overlay). Cardiomyocytes were identified with antibodies to a-actinin (C and G) or desmin (K and O) (both blue in overlay). Nuclei were stained 
with TOPRO (B, F, J, and N; red in overlay). Nuclear accumulation of zyxin was observed either following ANP treatment or in transgenic mice 
expressing cardiac-specific GC (GC Tg). (Q-JJ) Control (Q-T and CC-FF) or experimental (U-BB and GG-JJ) mouse hearts labeled with 
antibody to phospho-Akt473 (Q, U, Y, CC, GG; yellow in overlay in panels X, BB, and JJ is due to coincident nuclear staining). Cardiomyocytes 
were identified with staining for desmin (S, W, AA, EE, and II; blue in overlays), and nuclei were identified by staining with TOPRO (R, V, Z, DD, 
and HH; red in overlays). Nuclear accumulation of phospho-Akt473 was observed following cGMP treatment (U-X; 5 hr intravenous), ANP treat­
ment (Y-BB), andn in the cardiac-specific GC Tg mouse hearts (GG-JJ). (KK) Immunoblot of cardiac protein lysates from fractions of control or 
ANP-treated mice partitioned into nuclear and cytoplasmic/membrane fractions. Enrichment of zyxin or phospho-Akt473 was observed in samples 
from ANP-treated mice. Enrichment for nuclei was demonstrated by partitioning of GAPDH (cytoplasmic), histone H3 (nuclear), and connexin 
43 (membrane associated) to appropriate fractions. Appropriate mobilities of bands on blots were confirmed using molecular weight standards 
in combination with labeling of unfractionated lysate (not shown). Scale bars: 10 |<m.
or im m unoprecip itates using an irrelevant co n tro l antibody, 
whereas zyxin im m unoreactiv ity was evident in sam ples pre­
pared from  cardiomyocyte cultures treated with 10 9 M  ANP that 
increased within 1 hour after induction (Figure 10). Reciprocal 
im m unoprecipitation experiments (IP for zyxin, then probe blot
for Akt) yielded decreased signals for Akt (data not shown). Pos­
sible explanations for this finding include the following: (a) the 
zyxin antibodies available do n o t recognize the com plex with 
Akt as efficiently as the noncom plexed form  o f  the protein (epi­
tope m asking, con form ational changes, etc.); (b) there may be
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F ig u re  10
Cardioprotective stimuli induce association of activated Akt with zyxin. 
Lysates (300 mg total protein) prepared from cultured cardiomyocytes 
treated with vehicle (control) or ANP (10~9 M for 30 or 60 minutes) 
were immunoprecipitated with anti-phospho-Akt473 antibody, and 
presence of zyxin was detected by subsequent immunoblotting with 
anti-zyxin antibody. Whole cell lysate prior to immunoprecipitation is 
shown to indicate presence of zyxin (positive control). Immunolabeling 
with phospho-Akt473 antibody confirmed immunoprecipitation of protein 
(p-Akt). Immunoprecipitation with irrelevant antibody to anti-p16ink4a is 
shown as a negative control. WB, Western blot.
excess uncom plexed zyxin relative to activated Akt even in ANP- 
stim ulated cells; or (c) zyxin antibodies may not recognize native 
protein in solu tion as well as denatured protein on a blot.
Nuclear targeting o f  Akt induces nuclear accumulation o f  zyxin, and 
Akt activation is required fo r  nuclear zyxin accumulation. N uclear 
targeting o f  zyxin mediated nuclear accum ulation o f  phospho- 
A kt473 (Figure 4), and im m u noprecip itation  experim ents sug­
gested association between these 2 proteins (Figure 10). Thus, the 
capacity o f  Akt to serve in a reciprocal fashion to prom ote nucle­
ar accum ulation o f  zyxin was tested by adenoviral-mediated over­
expression o f  Akt in wild-type or nuclear-targeted forms followed 
by confocal microscopy to determine zyxin distribution and the 
effect o f  Akt inhibition upon accum ulation o f  zyxin in the nucle­
us. ANP-mediated nuclear accum ulation o f  zyxin in cultured car­
diomyocytes was blocked by inhibitors o f  Akt activity including 
L Y 294002, w ortm annin, and adenoviral-m ediated overexpres­
sion o f  dom inant-negative Akt (Figure 11, A and B). A lthough 
pharm acologic inhibition by LY294002 or w ortm annin effective­
ly blocked zyxin nuclear accum ulation (Figure 11B, blue bars), 
changes in zyxin distribution were evidenced by perinuclear (LY) 
or diffuse cytoplasm ic (w ortm annin) localization (Figure 11 A). 
Adenoviral infection with various Akt constructs was performed 
to clarify the requirem ent for Akt activation in nuclear accum u­
la tio n  o f  zyxin. N uclear accu m ulation  o f  zyxin resulted from  
overexpression o f  wild-type Akt that is likely due to elevation o f 
Akt activity, but overexpression o f  dom inant-negative Akt did 
not increase nuclear zyxin accum ulation (Figure 1 IB , green bars). 
Furtherm ore, dom inant-negative Akt inhibited  nuclear accu ­
m ulation o f  zyxin mediated by ANP treatm ent (Figure 11B, red 
bars). Requirem ent for Akt activation is supported by overexpres­
sion o f  nuclear-targeted Akt, which loses the ability to prom ote 
nuclear accum ulation o f  zyxin in the presence o f  LY 294002 or 
w ortm annin. Although nuclear-targeted Akt remained localized 
to the nucleus in the presence o f  the inhibitors, Akt activation 
as evaluated by im m unoreactivity with antibodies to phospho- 
Akt473 was lost (data not shown). Thus, localization o f  zyxin in 
the nucleus depends, in part, upon activation o f  Akt. M yocar­
dial section from  transgenic mice expressing nuclear-targeted 
Akt (32) also showed increased nuclear accum ulation o f  zyxin
com pared with nontransgenic control samples (Figure 11, C-L, 
arrows), confirm ing the ability o f  Akt to prom ote nuclear accu­
m ulation o f  zyxin in the context o f  the myocardium.
D is c u s s io n
Natriuretic peptide adm inistration exerts beneficial effects when 
used clinically for treatment o f  heart failure (13, 42) and in animal 
models to inhibit ischemic injury (43-45). Therapeutically, brain 
natriuretic peptide is infused at a rate o f  0 .01-0.03 (ig/kg/min versus 
ANP, which is infused at a concentration o f 0.025 (ig/kg/min, reach­
ing plasma concentrations o f  1.33 ng/ml (13) versus 1.6 x 10 10 M 
(3, 12), respectively. When used at levels close to physiological con­
centration (10 n M), ANP stim ulates cGM P-dependent protein 
kinase and Akt activation in human coronary arterial endothelial 
cells (46). Protective signaling induced by ANP could also account 
for suppression o f  serum deprivation-induced apoptosis in PC12 
cells (14). In neural tum or cell lines, low concentrations (10 *° M) 
o f  ANP or C type natriuretic peptide stimulated proliferation, but 
higher concentrations exerted antiproliferative action (47). Con­
sistent with our findings (Figure 1), natriuretic peptide concentra­
tion is a critical factor for influencing cell survival versus death, as 
apoptosis correlates with higher concentrations in dose-dependent 
exposure ranging from 10 9 M to 10 6 M (14-16 , 48). These results 
suggest that ANP exerts multiple independent actions upon target 
cells, including cardiomyocytes. A previous report linking ANP to 
prom otion o f  cardiomyocyte apoptosis at 10 6 to 10 9 M (48) never 
checked for short-term  antiapoptotic actions o f  ANP and used 
serum-starved (0%) cultures for assessment o f  apoptotic signaling. 
In our studies, serum starvation o f  myocyte cultures alone could 
prom ote apoptotic signaling, so the 2% serum concentration we 
used may have helped increase cell viability. Furthermore, we have 
observed in our system that apoptosis does occur in cardiac fibro­
blasts at the same low ANP concentrations that are protective for 
cardiomyocytes (10 9 to 10 m M, not shown). Last, it should be 
noted that the detection methodology used by our group (TUNHL) 
is markedly different from the approach employed in the Wu et al. 
study (48), which assessed apoptosis by visualization o f  nuclear 
morphology with fluorescent DNA-binding dyes H.33342 and prop- 
idium iodide. Potentiation o f  antiapoptotic signaling persisted after 
zyxin distribution has returned to the cytoskeleton (Figure 2C), so 
triggering o f  survival signaling involving zyxin translocation does 
not require long-term nuclear localization to maintain efficacy.
Nuclear accum ulation o f  zyxin as a m ediator o f  antiapoptotic 
signaling is an attractive candidate for participation in prom otion 
o f  Akt activity based upon prior observations linking nuclear accu­
m ulation o f  Akt with resistance to apoptotic stimuli (32). Akt acti­
vation enhances myocardial cell survival in vitro (28) and in vivo 
(27) and accumulates in the nucleus in response to cardioprotective 
stimuli such as IG F-1 or estrogen (31), but mechanisms o f  nuclear 
trafficking remain obscure. Correlations between localization o f 
zyxin and Akt in cells exposed to protective stim uli, observations 
indicating that presence o f  either protein in the nucleus promotes 
accumulation o f  its partner, and the induced coimmunoprecipita- 
tion o f  zyxin/Akt as a m ultim olecular com plex following protec­
tive stim ulation suggest interaction o f  these 2 proteins (although 
such interaction could certainly be indirectly brokered by addi­
tional as yet unidentified partners). At this point we do not know 
whether zyxin facilitates Akt transport to the nucleus or interacts 
with and helps retain Akt in the nucleus after arrival. Dependence 
o f  A kt transp ort or accum ulation  in the nucleus upon zyxin
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Nuclear-targeting of activated Akt induces nuclear accumulation of zyxin, and inhibition of Akt activation impairs nuclear accumulation of zyxin. 
Consequences of inhibiting Akt activation for zyxin nuclear localization (A and B) and Akt-mediated effects upon localization of zyxin in vivo (C-L). 
(A) Confocal micrographs of cultured cardiomyocytes treated with ANP alone or ANP following prior inhibitor treatments of LY294002 (LY) or 
wortmannin (WM). Distribution of zyxin (green in overlay) was influenced in all 3 groups, but inhibitor treatments prevented nuclear accumula­
tion of zyxin. Nuclei were labeled with TOPRO (blue in overlay), and phalloidin shows actin filament structure (red). Scale bar: 10 i<m (all scans 
in A at identical scale). (B) Bar graph shows the percentage of cells possessing nuclear localized zyxin following treatment with ANP (10~9 M) 
as assessed by confocal microscopy. Treatment groups from left to right are: no treatment with pharmacologic inhibitors; ANP treatment with or 
without pharmacologic inhibitors; adenoviral infections without ANP treatment; adenoviral infections with ANP treatment; and nuclear-targeted 
Akt (Akt-n.t.) adenoviral infection with and without pharmacologic inhibitors. *P < 0.005 relative to the control (first bar of each group) was found 
as indicated. Myocardial sections (C-L) show nuclear accumulation of zyxin in transgenic mice expressing cardiac-specific nuclear-targeted Akt 
(Akt-n.t. Tg) but not in nontransgenic control samples. Arrows indicate nuclei positive for both zyxin and Akt-n.t. Transgenic Akt-n.t. was visualized 
using antibody to myc-tag (tag) and desmin to show myofibrillar structure. Arrows indicate nuclei positive for both Akt-n.t. and zyxin. Nuclei were 
shown to correlate with Akt-n.t. labeling but are not included in overlay to facilitate presentation. Overlay colors correspond to Akt-n.t. (red), zyxin 
(green), and desmin (blue) with coincidence of red and blue labeling appearing yellow. Scale bars: 20 i<m (C-L).
remains to be determined in future studies. Since zyxin exhibits 
a propensity for nuclear shuttling (35), it is tem pting to postulate 
that the mechanism for nuclear accum ulation o f Akt in response 
to cardioprotective stim uli could involve zyxin. Characterization 
o f  the zyxin/Akt protein complex and identification o f  other possi­
ble members associated with these partners could provide valuable 
clues regarding molecular facilitators o f  nuclear trafficking and 
cell survival signaling (49). Since the carboxyl-LIM -dom ain pro­
tein family to which zyxin belongs consists o f multiple members, it 
is probable that functional redundancy for mediating Akt nuclear 
accumulation exists, since zyxin knockout mice are overtly normal 
(50) whereas Akt knockout mice exhibit clear phenotypic abnor­
malities (51). Paxillin, a related carboxyl-LIM domain family m em ­
ber (52), exhibits striking similarities to zyxin in response to sever­
al o f  the parameters tested in our study (Supplemental Figure S3), 
suggesting the potential for functional redundancy between zyxin 
and paxillin within the lim its o f our analyses.
Cardioprotective stimuli and Akt activation have been linked via 
stim ulation o f  cGM P production. Levels o f  cGM P rise following 
exposure to cardioprotective stim uli such as 1GF-1 (40), adreno- 
m edullin (38), estradiol (39), and natriuretic peptide, leading to 
models that dem onstrate biological effect(s) o f  natriuretic pep­
tides mediated by cGM P-dependent signaling (26). ln  a myocar­
dial context, ANP inhibits hypertrophy o f  neonatal and adult car­
diomyocytes through cGMP-dependent signaling involving pGC 
receptors (53 ,54). Sim ilar to dose-dependent effects o f  ANP upon 
cell survival, cGM P can promote (55, 56) or inhibit (57) apoptotic 
cell death. ANP-mediated effects were mimicked by m anipulation 
o f cGM P signaling (Figures 5 -7 ) that together with PKG involve­
ment (Figure 5) adds another piece to the emerging picture o f the 
ANP-dependent survival signaling cascade.
Nuclear accum ulation o f  zyxin in vivo is induced by circulating 
ANP (Figure 9), indicating this cardioprotective autocrine/para­
crine signaling mechanism operates in the myocardium. The short
2726 The Journal of Clinical Investigation http://www.jci.org Volume 115 Number 10 October 2005
r e s e a r c h  a r t i c l e
half life o f  ANP as measured in humans (10 -20  minutes; re f 58) or 
rats (a few minutes; re f  59) prompted use o f  an osm otic pump for 
prolonged release (Figure 9 , I-P). Clinically, our results are consis­
tent with elevation o f  plasm a cGM P following intravenous infu­
sion o f  ANP (12) and the beneficial effects o f  left ventricular assist 
device support leading to norm alization o f  natriuretic peptide 
levels and recovery o f  GC-A activity (60). The in vivo situation is 
complex and likely involves concurrent effects o f  GCs stimulated 
by activation o f  nitric oxide production (61).
N atriuretic peptide receptor desensitization occurs in conges­
tive heart failure (CHF) (62). Among patients with mild CHF, the 
plasm a cG M P level correlated  with the ANP level. In con trast, 
these correlations were n o t found in patients with severe CHF. 
T h is suggests that dow nregulation o f  natriuretic peptide recep­
tor in CH F could indeed attenuate ANP-m ediated effects due 
to lack o f  cG M P induction. Since mice in our study were n o t in 
heart failure, these issues are n o t a factor, b u t it is clearly im por­
tant to point out this lim itation when interpreting our results in 
the con text o f  therapeutic effects o f  exogenously adm inistered 
natriuretic peptides.
The paradigm o f  signal transduction elucidated in this study 
involving the nuclear accum ulation o f  zyxin and Akt provides 
d irections for future studies to unify the intracellular traffick ­
ing o f  cytoskeletal LIM p roteins to card iop rotection . Future 
studies will expand upon the relationship o f  LI'M-domain pro­
teins to cardioprotective stim ulation  and cGM P-m ediated sig­
naling, leading to better understanding o f  cardiac pathogenesis 
and novel therapeutic approaches for m olecular intervention in 
the pathogenesis o f  heart failure.
M etho ds
Cardiomyocyte preparation. Neonatal rat ventricular myocytes were 
isolated from hearts o f 2- to 3-day-old Sprague-Dawley rats by mul­
tiple rounds o f digestion using a combination o f collagenase type I 
(Worthington) and pancreatin as previously described (31), Cells pre­
pared in this way were preplated for 2 hours in M-199 plus 15% FBS to 
reduce nonmyocyte contamination and plated at various densities on 
either plastic chamber slides pretreated with laminin (Sigma-Aldrich) 
or 1% gelatin-coated tissue culture dishes. On the following day, myo­
cyte cultures were washed and refed with maintenance medium (M-199 
supplemented with 2% horse serum) prior to incubation for up to 3 
days. Bromodeoxyuridine was used to inhibit fibroblast proliferation, 
and 98-99% purity o f our cultures for cardiomyocytes was confirmed 
by direct observation with phalloidin labeling.
Adenoviruses. Adenoviruses for pyk2/RAFTK, GFP, p-gal, and nuclear- 
targeted Akt were prepared as previously described (31, 32, 37). GFP- 
tagged nuclear-targeted zyxin was cloned using overlap PCR as described 
(63), Nuclear-targeted zyxin adenovirus was created with external prim­
ers generated complementary to the 5' end o f enhanced GFP (EGFP) 
(Clontech) with a 5r Nhel site (PI) and the V end o f the myc tag and the 
nuclear localization sequence from pCMV/myc/nuc (Invitrogen) with a 
stop codon in frame and Sail at 3' terminus (P4AS), Internal primers 
were generated with 18 bp overlaps (36 mer total) into the upstream 
and downstream coding sequences o f the genes to be fused. The prim­
ers (P2S and P2AS) corresponding to the fusion region between the 3' 
end o f EGFP and the 5r end o f murine zyxin contained 18 bp o f each 
sequence for a total length o f 36 bp, as did the primers (P3S and P3AS) 
corresponding to the fusion region between the V end o f murine zyxin 
and the 5' end o f the nuclear localization sequence (NLS) concatamer, 
PCR was then performed on each fragment using the corresponding
primer sets with Hi-Fidelity Supermix (Invitrogen Corp.), and PCR frag­
ments were gel-purified. Fragments were then combined in equimolar 
ratios in Hi-Fidelity Supermix (Invitrogen Corp.), and fusion PCR was 
performed. The complete fusion gene was then ligated into pCRIITOPO 
using Invitrogen’s TOPO-TA cloning kit. Colonies were analyzed by PCR, 
and positive colonies were grown, miniprepped, and sent for complete 
sequencing, A plasmid containing the verified sequence for the EGFP- 
Zyxin-NLS cDNA was digested with Nhel and Sail, and the resultant 2,5-kb 
GFP-Zyxin-NLS fragment was gel isolated and ligated into pDC315io 
(Microbix), Resultant colonies were analyzed by PCR, miniprepped, and 
confirmed by sequencing. The plasmid with the verified sequence was 
subsequently cotransfected in an equimolar ratio with pBHGloxAEl,3Cre 
(Microbix) using PolyFect transfection reagent (QIAGEN) into passage 
14 293iq cells from Microbix to generate the adenovirus. Appropriate 
expression o f the protein of interest was confirmed by immunoblot and 
immunohistochemistry of infected cardiomyocytes.
Transgenic mouse lines. All animal procedures were approved by the Insti­
tutional Animal Care and Use Committee o f San Diego State University, 
Transgenic mice expressing cardiac-specific nuclear-targeted Akt were pre­
viously described (32), and mice expressing cardiac-specific constitutively 
active GC (41) were generously provided by Christian Deschepper (Insti- 
tut de Recherches Cliniques, Montreal, Quebec, Canada), Nuclear-target­
ed zyxin transgenic mice were generated using the pDCGFP-Zyxin-NLS 
plasmid digested with Nhel/Sall, and the resulting 2,5-kb GFP-Zyxin- 
NLS fragment was gel purified. The fragment was subsequently ligated 
downstream of the Nhel/XhoI-digested aMHC promoter plasmid (kindly 
provided by Jeffrey Robbins, Children’s Hospital Medical Center, Cincin­
nati, Ohio, USA), Colony PCR was performed, and positive plasmids were 
miniprepped and sent for sequencing. The c26L,5GFP-Zyxin-NLS, 14 
sequenced plasmid was subsequently digested with BamHl to release the 
plasmid backbone, and the 8,5 kb promoter and cDNA gel purified and 
microinjected using established protocols into 0,5 dpc (days post coitum) 
FVBN/J embryos. Resulting founders were analyzed by PCR using prim­
ers aMHC (-550): GAATCACACCTGGGGTTCCC and EGFP (+140): 
TCAGGGTCAGCTTGCCGTAG and cycling conditions o f 95°C for 3 
minutes, 33 cycles of 95°C for 30 seconds, 57°C for 30 seconds, 72°C for
1 minute, and a final hold at 72°C for 10 minutes resulting in a 703-bp 
product. Positive founders were backcrossed to FVBN/J to produce nucle­
ar-targeted zyxin mice used in the experiments,
Immunoblotting. Whole cell lysates were prepared from cultured cells 
by first washing cardiomyocytes twice with PBS, then directly adding 
cell culture lysis buffer as previously described (64), Tissue lysates from 
cardiac tissue were prepared from hearts collected from 6- to 8-week-old 
mice and homogenized in tissue lysis buffer as previously described (65), 
Enrichment for nuclear fractions o f samples was performed using the 
NE-PERkit as recommended by the manufacturer (Pierce Biotechnology 
Inc.), Extracts were briefly sonicated and microfuged 10 minutes prior 
to electrophoresis. Fifty jxg per lane of protein was mixed with an equal 
volume o f sample buffer and boiled for 5 minutes before being loaded 
onto a 10% SDS-PAGE gel for electrophoresis. Separated proteins were 
transferred to Hybond transfer membranes (Amersham Pharmacia Bio­
tech) using a Trans-Blot Cell (Bio-Rad Laboratories) at 145 V for 3 hours 
at 4°C, Blots were rinsed in water, washed in TBST (50 mmol/1 Tris- 
Hcl pH 7,6, 150 mM NaCl, and 0,1% Tween 20) and incubated 1 hour 
in blocking solution (5% BSA in TBST), Blots were incubated overnight 
at 4°C in primary antibodies against either zyxin (Sigma-Aldrich) or 
cleaved caspase-3 (Cell Signaling Technology) dissolved in blocking solu­
tion, The next day, membranes were washed 3 times, 5 minutes each, in 
TBST prior to a 1-hour incubation at 25 °C with fluorescent-conjugated 
secondary antibody (Jackson Laboratory) dissolved in blocking solution.
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Membranes were washed and reactive proteins visualized by fluorescence 
using a Typhoon 9410 scanner (GE Healthcare), Quantitation o f zyxin 
and cleaved caspase-3 protein content was performed using ImageQuant
1,2 software provided with the Typhoon scanner, Histone H3 (Cell Sig­
naling Technology) immunolabeling was used to standardize protein 
loading among nuclear extracts. Partitioning o f the membrane fraction 
was verified using antibody to connexin 43 (Zymed Laboratories Inc.), 
Immunoprecipitation protocol. Neonatal cardiomyocytes were grown in 
150-mm plates to confluence. Cells were scraped and lysed in 400 jxl o f 
immunoprecipitation buffer on ice following sonication for 1 second 8 
times. The immunoprecipitation buffer had the same constitutents as 
lysis buffer for immunoblot protocols. Antibodies to phospho-Akt473 
(BioSource International), zyxin (Santa Cruz Biotechnology Inc.), paxil­
lin (BD Transduction Laboratories; BD Biosciences — Pharmingen), or 
PI3-K (Upstate) were added at a dilution o f 1:100 in a total volume o f 
500 fil, and immunoprecipitation was performed at 4°C overnight with 
constant mixing. Protein G beads (25 jxl) were added, and the solution 
was allowed to mix for 3 hours at 4°C, Protein G beads were washed 3 
times using the immunoprecipitation buffer and then prepared for PAGE 
by suspension in PAGE sample buffer,
Confocal microscopy. Cardiomyocytes cultured in 2-well chamber slides 
were rinsed in PBS and fixed in 4% paraformaldehyde. Cells were sub­
sequently rehydrated in PBS for 10 minutes, washed in PBS containing
0,1 mM glycine for 5 minutes, rinsed briefly in PBS, permeabilized in 
PBS containing 0,5% Triton X-100, washed twice in 3-minute PBS rinses, 
and blocked for 1 hour in PBS containing 10% horse serum. Slides were 
incubated overnight at 4°C with primary antibodies diluted in block­
ing solution. The next day, slides were washed 3 times for 10 minutes 
each time in PBS and incubated for 1 hour at room temperature in the 
dark, with secondary antibodies conjugated to either FITC or Texas Red 
diluted 1:100 in blocking solution (Jackson ImmunoResearch Laborato­
ries Inc.), After secondary labeling, slides were washed 3 times in PBS for
5 minutes per wash and mounted for viewing in VECTASHIELD medium 
(Vector Laboratories), Confocal images were acquired using a Molecular 
Dynamics CLSM 2010 as previously described (31), For identification 
o f zyxin, rabbit anti-zyxin (Sigma-Aldrich) was used as a primary Ab 
and was followed by FITC-conjugated donkey anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories), Desmin was detected by goat anti-des- 
min (Santa Cruz Biotechnology Inc.) followed by Texas Red-conjugated 
donkey anti-goat IgG (Jackson ImmunoResearch Laboratories), Rabbit 
anti-phospho-Akt473 (BioSource International) was used as a primary 
antibody to identify phospho-Akt473, followed by FITC-conjugated don­
key anti-rabbit IgG (Jackson ImmunoResearch Laboratories), The myc- 
tag o f nuclear-targeted Akt was detected by mouse anti-c-myc (Santa 
Cruz Biotechnology Inc.) followed by Texas Red-conjugated donkey 
anti-mouse IgG (Jackson ImmunoResearch Laboratories), Paxillin was 
detected by anti-paxillin antibody (BD Transduction Laboratories; BD 
Biosciences — Pharmingen), TOPRO-3 (Invitrogen Corp.) staining was 
performed to determine the localization of nuclei.
In intro treatments. Estradiol, adrenomedullin, IGF-1, PMA, forskolin, 
KT5823, and atrial natriuretic peptide were purchased from Sigma- 
Aldrich, HS142-1, a natriuretic peptide receptor A- and B-specific 
inhibitor, was a generous gift from H, Yano (Kyowa Hakko Kogyo Co., 
Tokyo, Japan), Cultures were treated with KT5823 or HS-142 1 hour 
prior to ANP stimulation. The cGMP analog used was cell permeable 
8 bromoguanosine 3’, 5'-cyclic monophosphate sodium salt monohy­
drate (B1893; Sigma-Aldrich),
In vivo treatments. Subcutaneously implanted osmotic pumps (200 fil, 
ALZET) containing ANP (10'4 M) were employed for 24 hours. Intrave­
nous infusion of saline and ANP was done through the tail vein at a rate
of approximately 50 jxl/min, Infusion volumes were finally adjusted to 
100 fil before administration.
Histological analyses. Sections were prepared from hearts that were fixed 
for 24 hours in neutral buffered formalin at room temperature. Paraf­
fin-embedded tissue sections were prepared from mouse hearts that had 
been fixed in formalin overnight at 4°C, The next day, hearts were infil­
trated with paraffin by an automated tissue processor. Paraffin-embed­
ded hearts were sectioned at a thickness o f 5 fim followed by deparaf- 
finization and rehydration,
Apoptosis determination assays. For TUNEL assays, cells were fixed and 
then labeled using terminal deoxyribonucleotidyl transferase accord­
ing to the manufacturer’s instructions (In Situ Apoptosis Detection 
Kit; Roche Diagnostics Corp.), In the colorimetric assay, apoptotic cells 
appeared as bright orange. Quantitative colocalization analysis for 
TUNEL positive nuclei was performed using CoLocalizer Pro version
1,2 (CoLocalization Research Software), DNA laddering was analyzed 
as described (66), DNA fragments (20 fig each) were separated by 1,2% 
agarose gel electrophoresis.
Statistics. Results are expressed as means ± SEM, Differences in quanti­
tative variables were examined by 1-way ANOVA and Tukey post hoc test 
for multiple comparisons,
ANP ELISA. ELISAs for ANP were performed using the ANF Rat (1-28) 
Immunoassay kit (89995; Peninsula Laboratories), Serum samples were 
drawn on anesthetized mice via cardiac puncture into syringes containing 
2,7 mM EDTA, 600 pM PMSF, and 200 KIU aprotinin, and centrifuged at 
16,000g, 4°C for 15 minutes. Isolated serum was extracted over aSep-Pak 
C-18 cartridge (Y1000; Peninsula Laboratories) per kit instructions, resus­
pended in ELISA buffer, and analyzed.
Ex two ischemia/reperfusion and hemodynamic analyses. Hearts were excised 
and treated in a Langendorff model system as previously described (67), 
In brief, hearts were removed and placed in chilled Krebs buffer for aortic 
cannulation. Perfused hearts were mounted on the Langendorff system at 
80 mm Hg aortic pressure, and a balloon was placed into the left ventricle 
on a closed system containing a Millar transducer. Hearts were perfused 
for a 30-minute equilibration period followed by 30 minutes o f no-flow 
ischemia, after which fluid flow was resumed for a reperfusion time o f
2 hours followed by 5-minute perfusion with neutral buffered formalin. 
Pressure measurements were recorded using an ADInstruments PowerLab 
system. Data was graphed as the percentage of preischemic left ventricular 
developed pressure. Five mice were used for each group except for the NT 
overexpressors where 4 animals were studied, ANOVA was done using SPSS 
software version 11,0 (SPSS Inc.) and a Newman-Keuls post hoc analysis. 
Inhibitor experiments. Neonatal cardiomyocytes were infected with ade­
noviruses for P-gal, dominant-negative Akt (kindly provided by Thomas 
Franke, Columbia University, New York, New York, USA), nuclear-tar­
geted Akt, and wild-type Akt for 2 hours. Following infection, cultured 
cardiomyocytes plated on chamber slides were refed with M l99 and 2% 
FBS, Cells that were not infected were serum starved in M l99 and 2% FBS 
for 24 hours prior to treatments. After 24 hours, cells were treated with 
50 fiM LY294002 or 100 nM wortmannin (both purchased from Sigma- 
Aldrich) for 1 hour prior to the 1-hour ANP (10-9 M) treatment. Following 
ANP treatment, cells were prepared for immunofluorescence microscopy. 
The number o f cells with nuclear localized zyxin were counted on a fluo­
rescent scope for each treatment condition and slide.
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